Review of Biological Agents in the Therapeutic Management of Monogenic Genodermatoses

Monogenic genodermatoses encompass a diverse group of over 400 distinct disorders, presenting significant therapeutic challenges. Recent advancements in the clinical application of biological agents have heralded a new era in the management of these conditions. A plethora of clinical studies and case reports have demonstrated the efficacy of TNF‐α, IL‐1, IL‐4Rα, IL‐17A, IL‐12/23, and IL‐6R inhibitors in the management of monogenic genodermatoses. To elucidate the current landscape of biological agent utilization and their putative mechanisms of action in the context of monogenic genodermatoses, we conducted a review of the literature.